A Study of How Safe Abrocitinib (CIBINQO) is in Pregnant Women and Their Offspring
← catalyst calendarNCT05721937 · readout in 499 d
Sponsored by Pfizer (industry) · PFE — their whole pipeline →. With PPD Development, LP.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
400estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-07-25 | actual | When the study began enrolling |
| Primary completion | 2027-12-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-12-31 | estimated | The whole study's end, after follow-up |
| First posted | 2023-02-10 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-12-09 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Atopic Dermatitis
Intervention
- Drug: Abrocitinib
Primary outcome
what the primary-completion date above is the date OFPercent of live birth children with major congenital malformations
measured Enrollment until 12 months after delivery
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed